Incyte And Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvotm (Axatilimab-Csfr) 9 Mg And 22 ...
(MENAFN- PR Newswire) – U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial …